Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep775 | Developmental endocrinology | ECE2017

GH influences plasma fasting adropin concentration in patients with turner syndrome

Wikiera Beata , Krawczyk Magdalena , Noczynska Anna , Daroszewski Jacek

Background: Increased adiposity and insulin resistance are conditions frequently observed nowadays. Many hormones are involved in the pathogenesis of the condition but therapeutic options we can offer to the patients are still scant. Each newly discovered peptide give us hope. Adropin (Ad) is a newly discovered metabolic hormone involved in energy homeostasis. This homeostasis is frequently disturbed in patient with Turner Syndrome (TS). Patient with Turner syndrome are unique...

ea0035p1028 | Thyroid (non-cancer) | ECE2014

The role of peroxisome proliferator-activated receptors α polymorphisms in Graves' disease and orbitopathy

Janusz Przemyslaw , Pawlak-Adamska Edyta , Bolanowski Marek , Daroszewski Jacek

Understanding the genetic etiology of Graves’ disease (GD) and Graves’ orbitopathy (GO) is recognized as an urgent priority. Since peroxisome proliferator-activated receptors α (PPARα) exhibit anti-inflammatory and immunomodulatory activity, and are required for the control of the adipose inflammation process their role in the GD and GO pathogenesis has been proposed. Abnormal expression and/or function of PPARα could suppress the inflammatory response...

ea0070aep910 | Thyroid | ECE2020

The use of single dose of rituximab in combination with radiotherapy, in the treatment of Graves’ Orbitopathy – clinical observations

Gojny Łukasz , Moskwa Agnieszka , Bolanowski Marek , Daroszewski Jacek

The treatment of orbitopathy in the course of Graves’ disease (GO, Graves’ Orbitopathy) still remains a serious therapeutic challenge. Modification of risk factors is considered to be the most important and the most effective method of treatment of benign GO. Treatment with intravenous glucocorticosteroid preparations remains the first-line therapy for moderate- to severe GO but is insufficient in some patients. Radiotherapy has been used in active GO therapy for d...

ea0022p813 | Thyroid | ECE2010

Association of Pro12Ala PPAR-γ gene polymorphism with Graves' orbitopathy

Daroszewski Jacek , Pawlak Edyta , Bolanowski Marek , Frydecka Irena

Introduction: Peroxisome proliferation-activated receptors-γ (PPAR-γ) have been shown to be involved in adipogenesis as well as in immunoregulation and inflammation control. Orbital fibroblast differentiation to adipocytes is a PPAR-γ dependent process essential for pathogenic tissue remodeling in Graves orbitopathy (GO).Purpose: We studied the occurrence and possible associations of the Pro115Gln and Pro12Ala in the ...

ea0014p336 | (1) | ECE2007

Soluble CTLA-4 is increased in Graves’ disease and not related to thyroid status or ophthalmopathy severity

Daroszewski Jacek , Pawlak Edyta , Bolanowski Marek , Slowik Miroslaw , Frydecka Irena

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a B7-binding protein that plays an important role in the down-regulation of T-cell activation. CTLA-4 function is closely associated with predisposition to autoimmune diseases. A native soluble form of CTLA-4 (sCTLA-4) is reported to be present in the sera of patients suffering from autoimmune thyroid disease. In this study we report data on sCTLA-4 concentrations in patients with clinical expression of Graves’ disease.<p c...

ea0081rc1.3 | Rapid Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2022

Plasma amino acid profile in women with polycystic ovary syndrome and its correlation with metabolic disturbances

Paczkowska Katarzyna , Rachon Dominik , Berg Andrzej , Siomkajlo Marta , Rybka Jacek , Kapczynska Katarzyna , Bolanowski Marek , Daroszewski Jacek

Background: Polycystic ovary syndrome (PCOS) is a heterogenous endocrinopathy commonly diagnosed in reproductive age women, predisposing to the development of metabolic disturbances. However, the mechanisms underlying the connection between PCOS and metabolic disorders are still not well understood. The aim of the study was to investigate amino acid (AA) profile in women with PCOS and to assess its relation with metabolic disturbances.Methods: 326 women:...

ea0049gp72 | Diabetes &amp; complications 1 | ECE2017

Specific plasma amino acids alternations associated with metabolic syndrome

Siomkajło Marta , Rybka Jacek , Gamian Andrzej , Stankiewicz-Olczyk Joanna , Bolanowski Marek , Daroszewski Jacek

Objectives: Amino acids (AA) plasma profile is associated with cardiometabolic diseases (CMD), predicts diabetes mellitus type 2 (DM2) and cardiovascular diseases (CVD) many years in advance. Metabolic syndrome (MS) defines the area of metabolic disturbances that precede DM2 and CVD development. The primary objective of the study was to examine the association between BCAA (branched chain amino acids), AAA (aromatic amino acids) profile and MS’s phenotype and to evaluate ...

ea0037ep343 | Diabetes (pathiophysiology &amp; epitemiology) | ECE2015

Irisin plasma level is connected with the android adipose tissue deposit

Pukajlo Katarzyna , Kolackov Katarzyna , Laczmanski Lukasz , Kuliczkowska-Plaksej Justyna , Bolanowski Marek , Milewicz Andrzej , Daroszewski Jacek

Irisin (Ir), a recently identified adipomyokine, cleaved and secreted to the circulation from the FNDC5 protein in response to physical activity and some environmental conditions has been postulated to induces the differentiation of a subset of white adipocytes into brown fat and mediates the beneficial effects of exercise on metabolic homeostasis. Polycystic ovary syndrome (PCOS) – one of the most frequent endocrinopathies affecting women of child-bearing age is associat...

ea0037ep344 | Diabetes (pathiophysiology &amp; epitemiology) | ECE2015

The GH treatment results in the increase of irisin concentration in plasma

Wikiera Beata , Pukajlo Katarzyna , Laczmanski Lukasz , Sloka Natalia , Basiak Aleksander , Bolanowski Marek , Noczynska Anna , Daroszewski Jacek

Brown adipose tissue metabolism is of remarkable pathophysiological interest, because it could be a target for future therapies for obesity and metabolic syndrome. Irisin (Ir), recently identified novel adipomyokine is essential in a white-to-brown fatty tissue transdifferentiation, and mediates some of the positive influences on metabolic disorders through increase of energy expenditure. The exact regulation of Ir secretion and action is unknown but significant positive assoc...

ea0035p758 | Obesity | ECE2014

Irisin plasma concentration in PCOS and healthy subjects is related to body adipose content

Pukajlo Katarzyna , Kolackov Katarzyna , Laczmanski Lukasz , Kuliczkowska-Plaksej Justyna , Lenarcik-Kabza Agnieszka , Milewicz Andrzej , Daroszewski Jacek

Polycystic ovary syndrome (PCOS) is a common endocrine abnormality connected not only with reproductive problems but also with impaired energy homeostasis leading to metabolic disorders including metabolic syndrome. Irisin (Ir), recently identified novel myokine, has been proposed to mediate some of the positive influence on metabolic disorders. The aim of our study was to search the relationship between Ir plasma concentration in PCOS in the context of metabolic disturbances....